Bone marrow and serum concentrations of 25-hydroxyvitamin D, 24,25-dihydroxyvitamin D, and 1 alpha,25-dihydroxyvitamin D in patients with leukemia and normal subjects.

Abstract

Concentrations of 25-hydroxyvitamin D (25-OH-D), 24,25-dihydroxyvitamin D [24,25(OH)2D], and 1 alpha,25-dihydroxyvitamin D [1,25(OH)2D] in bone marrow and serum of patients with leukemia and normal subjects were assayed. There were highly significant correlations between the bone marrow and serum concentrations of the respective vitamin D metabolites. Especially, the concentrations of 25-OH-D and 1,25(OH)2D in the bone marrow gave very similar values to those in serum. This is a big advantage in controlling the bone marrow levels of vitamin D metabolites in patients with leukemia, because doctors can calculate the bone marrow levels from the serum levels of the respective vitamin D metabolites without bone marrow aspiration. When 1 alpha-hydroxyvitamin D3 (1 alpha-OH-D3) was administered orally to eight patients with leukemia, clinical conditions were improved in seven patients: four complete remissions (CR), one partial response (PR), and two minor responses (MR) without severe hypercalcemia. The results suggest that the therapy with 1 alpha-OH-D3 is fairly effective for curing human leukemia although it is not dramatic.

• Authors: S Masuda, T Okano, K Noma, M Hamasaki, T Kobayashi, H Oh, S Yoshida
• Journal: Journal of nutritional science and vitaminology (J Nutr Sci Vitaminol (Tokyo)) Vol. 35 Issue 4 Pg. 211-23 (Aug 1989) ISSN: 0301-4800 [Print] Japan
• PMID: 2585143 (Publication Type: Journal Article)

Chemical References

• Hydroxycholecalciferols
• Phosphorus
• Calcium
• alfacalcidol

Topics

• Adult
• Bone Marrow (metabolism)
• Calcium (metabolism)
• Female
• Humans
• Hydroxycholecalciferols (blood, metabolism, therapeutic use)
• Leukemia, Myeloid, Acute (drug therapy, metabolism)
• Male
• Middle Aged
• Myelodysplastic Syndromes (drug therapy, metabolism)
• Phosphorus (metabolism)